SCHEMBL252382

SCHEMBL252382

O=C(O)Nc1cn2nc(Cn3nnc4ccc(Br)cc43)ccc2n1

nearest known ligand 0.36

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
CSNK1D P48730 3/20 0.36
CSNK1E P49674 3/20 0.36
MGAM O43451 2/20 0.33
AMY1A P0DUB6 2/20 0.33
GAA P10253 2/20 0.33
SI P14410 2/20 0.33
MGAM2 Q2M2H8 2/20 0.33
KMO O15229 2/20 0.33
PIK3CA P42336 4/20 0.33
RAB9A P51151 1/20 0.32
BRD4 O60885 1/20 0.32
SLC2A1 P11166 1/20 0.32
SLC2A2 P11168 1/20 0.32
SLC2A3 P11169 1/20 0.32
SLC2A4 P14672 1/20 0.32
RIPK1 Q13546 2/20 0.31
PTK2 Q05397 2/20 0.31
HDAC8 Q9BY41 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1550773 0.89 KDR (0.43) CSNK1DCSNK1E
SCHEMBL251928 0.86 CSNK1D (0.33) CSNK1DCSNK1EPIK3CARAB9ABRD4
SCHEMBL252919 0.85 MGAM (0.34) MGAMAMY1AGAASIMGAM2
SCHEMBL5953862 0.82 KDM4E (0.38) MGAMAMY1AGAASIMGAM2
SCHEMBL253221 0.80 PIK3CG (0.36) MGAMAMY1AGAASIMGAM2
SCHEMBL252109 0.80 KDM4E (0.46) GAARAB9A
Hydrochloric Acid SCHEMBL251752 0.79 PIK3CG (0.35) PTK2
SCHEMBL1551274 0.79 KDR (0.45) CSNK1DCSNK1ERIPK1
SCHEMBL5953693 0.78 BRD4 (0.39) GAARAB9ABRD4
SCHEMBL2746330 0.78 CSNK1D (0.45) CSNK1DCSNK1ERIPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2313407-B1 cMET INHIBITORS TAKEDA PHARMACEUTICAL (JP) 2016-10-05 EP disclosed
US-20130315895-A1 COMBINATION OF A cMET INHIBITOR AND AN ANTIBODY TO HGF AND/OR cMET TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2013-11-28 US disclosed
EP-2588107-A1 COMBINATION OF A cMET INHIBITOR AND AN ANTIBODY TO HGF AND/OR cMET Takeda Pharmaceutical Company Limited (JP) 2013-05-08 EP disclosed
US-8178534-B2 cMET inhibitors TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-05-15 US disclosed
WO-2012003338-A1 COMBINATION OF A cMET INHIBITOR AND AN ANTIBODY TO HGF AND/OR cMET TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-01-05 WO disclosed
EP-2313407-A1 cMET INHIBITORS Takeda Pharmaceutical Company Limited (JP) 2011-04-27 EP disclosed
US-20100063054-A1 cMET INHIBITORS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-03-11 US disclosed
WO-2010019899-A1 cMET INHIBITORS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-02-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130315895-A1 COMBINATION OF A cMET INHIBITOR AND AN ANTIBODY TO HGF AND/OR cMET HGF, MET, HGFAC CSNK1D 2737/4885CSNK1E 1156/4885MGAM 481/4885
US-20100063054-A1 cMET INHIBITORS CEPT1, LCAT, GNMT CSNK1D 225/4885CSNK1E 119/4885MGAM 971/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.